Brivaracetam
CHEBI:CHEBI_133013
Definition
A non-proteinogenic amino acid derivative that is butanamide in which the pro-S hydrogen at position 2 is replaced by a (4R)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy.
Chemical Information
- Molecular Formula
- C11H20N2O2
- Molecular Mass
- 212.289
- Charge
- 0
- SMILES
- N1([C@H](C(N)=O)CC)C(C[C@H](C1)CCC)=O
- InChI
- InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1
- InChIKey
- MSYKRHVOOPPJKU-BDAKNGLRSA-N
Alternative Names
- (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
- 2-(2-Oxo-4-propylpyrrolidin-1-yl)butanamide
- brivaracetam
- Briviact
- UCB 34714
- UCB34714
Treatment Applications
-
cerebral creatine deficiency syndromeView Disease →
DOID:0050798
Drug Classification
-
gamma-lactamView Class →
CHEBI:74222
-
non-proteinogenic amino acid derivativeView Class →
CHEBI:83812
-
t99875
-
t100575
Important Medical Information
⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.
- Always consult with a healthcare professional before starting, stopping, or modifying any medication.
- Side effects may vary and this list may not be comprehensive.
- Drug interactions may occur with other medications.
Additional Identifiers
- core#notation
- CHEBI:133013
- DRON_00010000
- 1739745
- oboInOwl#hasDbXref
- Wikipedia:Brivaracetam
Additional References
🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.
Additional Attributes
- core#notation
- CHEBI:133013
- rxcui
- 1739788
- dea_schedule
- CV
- active_ingredient_strength
- 50 kg/50kg
- active_ingredient_name
- BRIVARACETAM
- package_marketing_start_date
- 26-MAY-15
- manufacturer_name
- UCB, Inc.
- unii
- U863JGG2IA
- spl_set_id
- 3cf2f439-0e97-443e-8e33-25ecef616f6c
- nui
- N0000192345
- pharm_class_moa
- Epoxide Hydrolase Inhibitors [MoA]
- pharm_class
- Epoxide Hydrolase Inhibitors [MoA]
- 22-rdf-syntax-ns#type
- http://www.w3.org/2002/07/owl#Class
- oboInOwl#hasOBONamespace
- chebi_ontology
- DRON_00010000
- 1739745
- generic_name
- BRIVARACETAM
- brand_name
- Briviact
- brand_name_base
- Briviact
- oboInOwl#hasDbXref
- Wikipedia:Brivaracetam
- oboInOwl#id
- CHEBI:133013
- product_type
- BULK INGREDIENT
- marketing_category
- BULK INGREDIENT
- listing_expiration_date
- 20241231
- dosage_form
- INJECTION, SUSPENSION
- marketing_start_date
- 20240128
- labeler_name
- Lee Pharma Limited
- product_ndc
- 16812-009
- application_number
- NDA205837
- RO_0000087
- http://purl.obolibrary.org/obo/CHEBI_35623
- oboInOwl#inSubset
- http://purl.obolibrary.org/obo/chebi#3_STAR
- chebi#has_functional_parent
- http://purl.obolibrary.org/obo/CHEBI_35619
- route
- INTRAVENOUS
- spl_id
- 0ea1e398-f858-3fef-e063-6394a90a867e
- package_ndc
- 16812-009-01
- package_description
- 1 BAG in 1 DRUM (16812-009-01) / 25 kg in 1 BAG
- has_treatment
- http://purl.obolibrary.org/obo/DOID_2234
- rdf-schema#range
- https://w3id.org/def/predibionto#has_drug_106632
- owl#annotatedSource
- t100687
- owl#someValuesFrom
- t2994889